Phase II Clinical Evaluation of Bryostatin 1 in Patients With Hodgkin's Disease
OBJECTIVES: I. Determine the response rate in patients with recurrent or refractory
Hodgkin's disease treated with bryostatin 1. II. Determine qualitative and quantitative
toxicities of bryostatin 1 in these patients. III. Determine duration of response and
survival in these patients.
OUTLINE: Patients receive bryostatin 1 by continuous IV infusion over 72 hours. Courses
repeat every 14 days in the absence of disease progression or unacceptable toxicity for at
least 4 courses. Patients who achieve complete response (CR) are treated with 4 additional
courses beyond CR.
PROJECTED ACCRUAL: A total of 14-27 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
David S. Eilender, MD
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|